Approved Drugs Boost Brown Fat Activation in Computational Repurposing Study

Two pharmaceutical agents currently approved for other clinical indications, Saxagliptin and Tolvaptan, significantly enhance the thermogenic activation and differentiation of human brown adipocytes, according to a research study published in Biology Direct. The investigation demonstrated that Saxagliptin and, to a lesser extent, Tolvaptan markedly stimulate brown adipose tissue differentiation and activation when tested in human thermogenic adipocytes. The candidates were identified through an unbiased, data-driven computational framework that evaluates drug-induced gene expression profiles against target cellular signatures. By integrating computational transcriptomic matching with laboratory validation in human cells, the researchers established that existing small molecules can be repurposed to promote brown adipocyte recruitment and thermogenic activity.

The research centers on the therapeutic promise of human brown adipose tissue, whose physiological recruitment and thermogenic function represent key targets for preventing and managing obesity and related metabolic complications. Activating thermogenesis in brown fat and expanding its cellular recruitment have emerged as compelling avenues for metabolic intervention. However, the study notes that conventional strategies focused on identifying and upregulating specific genes to drive brown fat recruitment and activation frequently face notable inefficiencies. In contrast, small molecules offer significant practical advantages for cell conversion, providing rapid and safe mechanisms capable of modulating cellular pathways without the complexities inherent to traditional gene-upregulation techniques.

To circumvent the limitations of conventional approaches, the research team utilized an unbiased transcriptomics methodology termed Drug Enhanced Cell Conversion using Differential Expression, or DECCODE. This computational strategy is designed to identify small molecules that facilitate cell conversion by systematically analyzing drug-induced gene expression patterns. This data-driven approach allows investigators to prioritize candidate molecules capable of steering cells toward a desired cellular lineage, streamlining the discovery of compounds that influence tissue differentiation and function.

The initial phase of the DECCODE workflow required establishing a definitive transcriptomic target profile representing functional human brown adipose tissue. To achieve this, the investigators generated brown adipocyte cells derived from human pluripotent stem cells to serve as the molecular benchmark. The researchers applied high-throughput RNA sequencing to capture the precise molecular characteristics of these cells. The study highlights that RNA-seq efficiently identifies the hallmark molecular features and transcriptional patterns that emerge during brown adipose tissue differentiation experiments, providing a reliable and robust baseline signature for subsequent computational comparisons.

With the transcriptomic profile of human pluripotent stem cell-derived brown adipocytes established as the target, the investigators screened small molecules from the Library of Integrated Network-based Cellular Signatures collection, known as LINCS. The team evaluated chemical compounds within the LINCS database to assess their degree of transcriptional similarity to the target brown adipocyte profile. Through this unbiased computational comparison, the DECCODE system prioritized a curated pool of candidate drugs that exhibited high alignment with brown adipose tissue activation signatures. This computational prioritization enabled the researchers to narrow an extensive chemical library down to specific, high-probability candidates.

The prioritized candidates were subsequently subjected to experimental validation in human thermogenic adipocytes to determine whether the computational predictions translated into actual biological activity. The laboratory experiments confirmed that two approved drugs, Saxagliptin and Tolvaptan, significantly enhanced thermogenic activation. The validation experiments further indicated that while Saxagliptin delivered robust improvements in both differentiation and activation, Tolvaptan also significantly boosted brown adipose tissue differentiation and activation, albeit to a lesser extent. These findings confirmed that transcriptomic signature matching successfully identified small molecules capable of functionally enhancing human brown adipocytes in an experimental setting.

The authors concluded that this unbiased in silico approach provides a practical, resource-efficient avenue for identifying small molecules with drug repurposing potential. By focusing on pharmaceutical compounds that have already secured approval for other indications, the methodology offers a streamlined pathway to explore new therapeutic applications. The researchers noted that while thorough experimental validation remains essential to confirm the functional efficacy of computationally identified candidates, the in silico framework itself is versatile. Consequently, this computational cell conversion strategy could be broadly applied across various cellular lineages to discover small molecules that regulate diverse cell types.

Subject of Research: Computational identification and validation of small molecules for brown adipocyte activation

Article Title: Data-driven identification of small molecules inducing brown adipocyte activation and differentiation

Article References: Napolitano, F., Rodriguez-Fdez, S., Chiarugi, D., Carobbio, S., Mali, I. D., Nigro, M., Navarro González, C., Gao, X., & Vidal-Puig, A. (2026). Data-driven identification of small molecules inducing brown adipocyte activation and differentiation. Biology Direct. https://doi.org/10.1186/s13062-026-00990-2

Image Credits: AI Generated

DOI: 10.1186/s13062-026-00990-2

Keywords: brown adipose tissue, brown adipocytes, thermogenic activation, adipocyte differentiation, Saxagliptin, Tolvaptan, DECCODE, transcriptomics, RNA-seq, pluripotent stem cells, LINCS library, drug repurposing, small molecules, cell conversion, obesity, metabolic complications, in silico screening, differential expression